Clinical evaluation of Alpine® vs. Xpedition® stent delivery system of the XIENCE® everolimus-eluting stent
Completed
- Conditions
- obstruction in the arteries that supply the heart with blood10011082significant coronary stenosis
- Registration Number
- NL-OMON45629
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 500
Inclusion Criteria
All patients undergoing PCI with EES, aged 18 years or older, will be considered for eligibility.
Exclusion Criteria
Patients will be excluded when scheduled for chronic total occlusion (CTO) PCI or if verbal informed consent cannot be obtained.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary endpoint is the proportion of procedures with crossing time (from<br /><br>introduction of guidewire to stent deployment) longer than 30 minutes.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary endpoints include procedural time (from heparin administration to<br /><br>removal of catheter sheath, mins), use of additional materials, total<br /><br>procedural costs, radiation dose (*Gym2), radiation time (mins), and contrast<br /><br>dose (ml).</p><br>